FutureChem Co

FutureChem Co Assets per Share

The Total Assets per Share of FutureChem Co (220100.KQ) as of Oct 22, 2026 is 3,372.90 KRW. In the previous year, Total Assets per Share was 3,367.96 KRW — a change of 0.15% (higher).

Assets per Share

3,372.90KRW

YoY

0.15%

Last updated:

Total Assets per Share of FutureChem Co is 2025 3,372.90 KRW. Total Assets per Share of FutureChem Co was 2024 3,367.96 KRW. It decreases by 0.15% higher compared to the previous year.

The FutureChem Co Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
2,898.46 KRW
Jan 1, 2019
2,860.81 KRW
Jan 1, 2020
3,731.61 KRW
Jan 1, 2021
3,490.81 KRW
Jan 1, 2022
4,014.87 KRW
Jan 1, 2023
3,296.08 KRW
Jan 1, 2024
3,367.96 KRW
Jan 1, 2025
3,372.90 KRW
The FutureChem Co Assets per Share history
YEARAssets per ShareYoY
3,372.90KRW+0.15%
3,367.96KRW+2.18%
3,296.08KRW-17.90%
4,014.87KRW+15.01%
3,490.81KRW-6.45%
3,731.61KRW+30.44%
2,860.81KRW-1.30%
2,898.46KRW+77.91%
1,629.19KRW+8.73%
1,498.32KRW+180.25%
534.65KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

FutureChem Co Stock analysis

What does FutureChem Co do? FutureChem Co., Ltd. generates revenue through the manufacture and distribution of radiopharmaceuticals, including diagnostic agents for lung cancer, Parkinson's disease, and Alzheimer's disease. The company produces medical automation modules such as cubes, disposable cassettes, reagent kits, radio-caps, and kryptofix kits, alongside PET and SPECT precursors for radiopharmaceuticals. These products are sold to healthcare providers, diagnostic centers, and medical facilities requiring specialized radiopharmaceutical solutions. The firm also develops metal chelating agents and fluorescence probes for medical applications. The primary buyers of FutureChem's products include hospitals, clinics, and research institutions focused on cancer diagnostics and neurological conditions. Medical automation modules and disposable goods are utilized in diagnostic procedures, while PET and SPECT precursors support imaging technologies. Metal chelating agents and fluorescence probes are integrated into medical testing and imaging processes. FutureChem's revenue streams are driven by the demand for advanced diagnostic tools in oncology and neurology. The company's portfolio targets healthcare segments requiring early detection of diseases, with products designed for both diagnostic imaging and laboratory testing. Sales are concentrated in medical facilities that prioritize precision diagnostics and specialized treatment planning. FutureChem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about FutureChem Co stock

Total Assets per Share of FutureChem Co is 3,372.90 KRW in 2025.

Total Assets per Share of FutureChem Co changed from 3,367.96 KRW to 3,372.90 KRW, representing a 0.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share FutureChem Co since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — FutureChem Co

All Key Metrics — FutureChem Co